» Articles » PMID: 36504899

A Multi-targeting Natural Product, Aiphanol, Inhibits Tumor Growth and Metastasis

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2022 Dec 12
PMID 36504899
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is one of the main causes of death in humans worldwide, the development of more effective anticancer drugs that can inhibit the malignant progression of cancer cells is of great significance. Aiphanol is a natural product identified from the seeds of and the rhizome of . Our preliminary studies revealed that it had potential antiangiogenic and antilymphangiogenic activity by directly targeting VEGFR2/3 and COX2 in endothelial cells. However, the influence of aiphanol on cancer cells per se remains largely undefined. In this study, the effects and related mechanisms of aiphanol on cancer growth and metastasis were evaluated and . Acute toxicity assay and pharmacokinetic analysis were utilized to investigate the safety profile and metabolism characteristics of aiphanol. We revealed that aiphanol inhibited the proliferation of various types of cancer cells and the growth of xenograft tumors in mice and zebrafish models. The possible mechanism was associated with the inactivation of multiple kinases, including FAK, AKT and ERK, and the upregulation of BAX and cleaved caspase-3 to promote cancer cell apoptosis. Aiphanol significantly inhibited cancer cell migration and invasion, which was related to the inhibition of epithelial-mesenchymal transition (EMT) and F-actin aggregation. Aiphanol effectively attenuated the metastasis of several types of cancer cells . In addition, aiphanol exerted no significant toxicity and had fast metabolism. Collectively, we demonstrated the anticancer effects of aiphanol and suggested that aiphanol has potential as a safe and effective therapeutic agent to treat cancer.

Citing Articles

Use of Drug Sensitisers to Improve Therapeutic Index in Cancer.

Chen Y, Jin E, Day P Pharmaceutics. 2024; 16(7).

PMID: 39065625 PMC: 11279903. DOI: 10.3390/pharmaceutics16070928.


Drug repositioning in thyroid cancer: from point mutations to gene fusions.

Sanchez-Marin D, Silva-Cazares M, Carmen M, Campos-Parra A Front Oncol. 2024; 14:1407511.

PMID: 38779099 PMC: 11109414. DOI: 10.3389/fonc.2024.1407511.


Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals.

Fakhri S, Moradi S, Abbaszadeh F, Faraji F, Amirian R, Sinha D Cancer Metastasis Rev. 2024; 43(1):261-292.

PMID: 38169011 DOI: 10.1007/s10555-023-10161-8.


Application of Zebrafish as a Model for Anti-Cancer Activity Evaluation and Toxicity Testing of Natural Products.

Shen Y, Sheng R, Guo R Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375774 PMC: 10305033. DOI: 10.3390/ph16060827.

References
1.
Wei M, Zong W, Cheng E, LINDSTEN T, Panoutsakopoulou V, Ross A . Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001; 292(5517):727-30. PMC: 3049805. DOI: 10.1126/science.1059108. View

2.
Vane J, Botting R . The mechanism of action of aspirin. Thromb Res. 2003; 110(5-6):255-8. DOI: 10.1016/s0049-3848(03)00379-7. View

3.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

4.
Farghadani R, Naidu R . Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer. Cancers (Basel). 2021; 13(14). PMC: 8307022. DOI: 10.3390/cancers13143427. View

5.
Ying J, Zhang M, Qiu X, Lu Y . The potential of herb medicines in the treatment of esophageal cancer. Biomed Pharmacother. 2018; 103:381-390. DOI: 10.1016/j.biopha.2018.04.088. View